Core Viewpoint - Fujian Pharmaceutical (300497.SZ) has established a new subsidiary, Weiran Alliance (Shanghai) Food Technology Co., Ltd., with a registered capital of 10 million yuan, aiming to leverage its location in the Yangtze River Delta to create a unique commercial entity for technology transfer in the protein industry [1] Group 1 - The new subsidiary has completed its business registration and obtained a business license from the Shanghai Xuhui District Market Supervision Administration [1] - The establishment of Weiran Alliance aims to build the "Weiran New Protein Co-Creation Alliance," focusing on brand building, product development, and customized marketing for member brands [1] - The initiative will initially attract overseas brands, with plans to incorporate domestic brands as new protein food materials gain recognition and approval in China, creating a dual-market synergy [1]

Core Viewpoint - Fujian Pharmaceutical (300497.SZ) has established a new subsidiary, Weiran Alliance (Shanghai) Food Technology Co., Ltd., with a registered capital of 10 million yuan, aiming to leverage its location in the Yangtze River Delta to create a unique commercial entity for technology transformation in the protein industry [1] Group 1 - The new subsidiary has completed its business registration and obtained a business license from the Shanghai Xuhui District Market Supervision Administration [1] - The establishment of Weiran Alliance aims to build a collaborative platform for new protein development, focusing on brand building, product research, and customized marketing [1] - The initiative will initially attract overseas brands, with plans to incorporate domestic brands as new protein raw materials gain recognition and approval in China, creating a dual-market synergy [1]

证券代码：300497 证券简称：富祥药业 公告编号：2025-063 江西富祥药业股份有限公司 8、经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技术转 让、技术推广；宠物食品及用品零售；货物进出口。（除依法须经批准的项目外，凭 营业执照依法自主开展经营活动）许可项目：食品销售；食品互联网销售。（依法须 经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准 文件或许可证件为准） 9、出资方式：货币出资 10、出资人及出资比例：江西富祥生物科技有限公司，持股100% 关于控股子公司投资设立孙公司并完成工商注册登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、对外投资概述 江西富祥药业股份有限公司（以下简称"公司"）的控股子公司江西富祥生物科 技有限公司以自有资金设立了未冉商盟（上海）食品科技有限公司，注册资本为1,000 万元人民币。根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公 司自律监管指引第2号—创业板上市公司规范运作》以及《公司章程》等相关规定， 本次投资未达到董事会和股东大会的审议标准 ...

Group 1 - The stock prices of Mengke Pharmaceutical dropped over 10% [1] - Borui Pharmaceutical and Baicheng Pharmaceutical experienced declines of over 7% [1] - Other companies such as Yuekang Pharmaceutical, Kangchen Pharmaceutical, Yuandong Biological, and Fuxiang Pharmaceutical also saw significant drops in their stock prices [1]

Core Viewpoint - Fujian Pharmaceutical Co., Ltd. has received approval for its amino acid water-soluble fertilizer product, allowing it to be sold in the domestic market [1] Group 1 - Fujian Pharmaceutical's subsidiary, Jiangxi Fujian Biotechnology Co., Ltd., is responsible for the newly approved fertilizer product [1] - The product has been granted a registration certificate by the National Agricultural and Rural Affairs Ministry's Fertilizer Registration Review Committee, with the registration number: Agricultural Fertilizer (2025) Approval No. 21015 [1] - This approval marks a significant milestone for the company, enabling it to expand its product offerings in the agricultural sector [1]

证券代码：300497 证券简称：富祥药业 公告编号：2025-062 江西富祥药业股份有限公司 关于控股子公司取得肥料登记证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 近日，经国家农业农村部肥料登记评审委员会审定，江西富祥药业股份有限公司 （以下简称"公司"）控股子公司江西富祥生物科技有限公司（以下简称"富祥生物"） 的含氨基酸水溶肥料产品准予肥料登记，登记证号：农肥（2025）准字21015号，标 志着公司的含氨基酸水溶肥料产品可以在国内市场上市销售。 特此公告。 江西富祥药业股份有限公司 董事会 2025 年 9 月 22 日 公司的含氨基酸水溶肥料含有植物生长所需的17种氨基酸和氮、磷、钾大量元素， 钙、镁、硫中量元素，以及锌、锰、铁、铜等微量元素。此外还含有丰富的小肽、核 酸、有机酸等营养物质，对植物的生长、生理代谢有明显的促进效果，尤其在促进生 根、光合作用、增加叶绿素、提高作物抗逆能力、改良土壤肥力等方面表现优异。目 前已完成田间试验，试验结果表明增产效果明显。 国家农业农村部于2022年印发《到2025年化肥减量化行动方案》，明确提 ...

Core Viewpoint - Fuxiang Pharmaceutical is expanding the production capacity of Piperacillin, which is a mainstream product in the market with broad demand [1] Group 1 - The company is focusing on increasing the capacity for Piperacillin production [1] - Piperacillin can be combined with Tazobactam and Sulbactam to form compound preparations, making it a popular choice in the market [1] - The demand for these products is significant, indicating a strong market opportunity for the company [1]

Core Viewpoint - The company, Fuxiang Pharmaceutical, has highlighted its leading position in the lithium battery electrolyte additive market, with strong shipment volumes and cost control capabilities, while also noting that prices for these additives are currently at historical lows, indicating limited room for further price declines [1] Group 1 - The company's lithium battery electrolyte additive products have shipment volumes and cost control capabilities that rank among the best in the industry [1] - The current prices of lithium battery electrolyte additives are at historical lows, suggesting that there is limited potential for further price decreases [1] - As the industry undergoes capacity clearing and the new energy sector experiences reduced competition, any rebound in product prices could significantly enhance the company's profitability [1]

Core Viewpoint - Company successfully completed the qualification supplier registration for its new triazole process product, tazobactam, which is expected to enhance production capacity, reduce production costs, and improve market competitiveness [1] Group 1 - The new triazole process for tazobactam has been successfully registered with downstream customers as a qualified supplier [1] - The expected release of production capacity will not only lower production costs but also increase the selling price of tazobactam [1] - The improvements in production efficiency are anticipated to enhance the company's market competitiveness [1]

Core Viewpoint - Fuxiang Pharmaceutical is experiencing a growth in its mid-year performance compared to last year, but it remains in a loss position. The company plans to improve its net profit through various products and strategies [2]. Group 1: Business Performance and Strategies - The company aims to enhance its pharmaceutical business by increasing the selling price of key intermediates and expanding production capacity for various products, which will improve gross margins and competitiveness [2]. - In the new energy sector, Fuxiang's lithium battery electrolyte additive products are performing well in terms of shipment volume and cost control, with prices at historical lows, indicating potential for profit growth as the industry recovers [2]. - The synthetic biology sector is being developed with a focus on microbial protein, with a new food raw material application already accepted for review by the National Health Commission, aiming for approval and market launch in the second half of the year [2][4]. Group 2: Microbial Protein Business Advantages - Fuxiang Pharmaceutical is a pioneer in the domestic microbial protein industry, with significant production capacity and proprietary technology, including patents in multiple countries [3]. - The company has achieved international advanced levels in key technologies for microbial protein production and has received various quality certifications for its products [3]. - Collaborations with academic institutions are in place to foster innovation across the entire industry chain, emphasizing green production and cost efficiency [3]. Group 3: Future Plans for Synthetic Biology - The company plans to obtain necessary approvals for its new protein products and enhance market presence through brand building and international expansion [4]. - Focus will be on accelerating the industrialization of new protein products and recruiting talent to build a high-performance team [4]. - Strategic partnerships have been established to advance product development and market promotion, with a strong outlook for amino acid water-soluble fertilizers [4].